profit from every $100 of sales.
$0$100
Regeneron Pharmaceuticals
$955.47+0.45% today
+37.5% in 1 year
1-year low $600.661-year high $973.36
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $21.94 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Regeneron Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from $12.2 billion in 2022 to $14.3 billion in 2025, with $4.50 billion of profit last year.
SalesProfit
Regeneron Pharmaceuticals handed back more cash to shareholders than it generated last year.
Buybacks $4.0B
Free cash flow 2025$3.8B
Bought back its own shares$4.0B
Paid as dividends$370M
Cash vs. debt$3.1B vs. $2.7B
Regeneron Pharmaceuticals vs. similar companies
Regeneron Pharmaceuticals grows the slowest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price | ||
 BeOne Medicines | 217.4× · Very expensive |
Compare Regeneron Pharmaceuticals with AbbVie · Amgen · Johnson & Johnson · Eli Lilly · Medtronic · Merck & · Roche · Thermo Fisher Scientific
AI analysis
An AI analyst reads Regeneron Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 8,497 | 16,072 | 12,173 | 13,117 | 14,202 | 14,343 | |
| – | – | 10,613 | 11,301 | 12,232 | 12,242 | |
| 3,577 | 8,947 | 4,739 | 4,047 | 3,991 | 3,702 | |
| 4,103 | 9,669 | 5,260 | 4,693 | 5,318 | 5,818 | |
| 3,513 | 8,075 | 4,338 | 3,954 | 4,413 | 4,505 | |
| 30.52 | 71.97 | 38.22 | 34.77 | 38.34 | 41.48 | |
| – | – | 87.2% | 86.2% | 86.1% | 85.4% | |
| 42.1% | 55.7% | 38.9% | 30.9% | 28.1% | 25.8% | |
| 41.3% | 50.2% | 35.6% | 30.1% | 31.1% | 31.4% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 17,163 | 25,435 | 29,215 | 33,080 | 37,759 | 40,559 |
| Cash | 2,194 | 2,886 | 3,106 | 2,730 | 2,488 | 3,118 |
| Total debt | – | – | 2,701 | 2,703 | 2,704 | 2,706 |
| Total liabilities | 6,138 | 6,666 | 6,551 | 7,107 | 8,406 | 9,302 |
| 11,025 | 18,769 | 22,664 | 25,973 | 29,354 | 31,257 | |
| 115 | 112 | 114 | 114 | 115 | 109 | |
| 27.7% | 39.5% | 15.3% | 11.8% | 11.9% | 12.3% | |
| 31.9% | 43.0% | 19.1% | 15.2% | 15.0% | 14.4% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 2,618 | 7,081 | 5,015 | 4,594 | 4,421 | 4,979 | |
| – | – | 1,617 | 926 | 882 | 1,214 | |
| – | – | 3,398 | 3,668 | 3,539 | 3,765 | |
| Dividends paid | – | – | – | 0 | 0 | 370 |
| – | – | 2,529 | 2,936 | 3,632 | 3,971 | |
| 432 | 602 | 725 | 885 | 983 | 994 |
Valuation
- 21.9×
- 20.7×
- 3.47
- 3.2×
- 6.9×
- 26.3×
- 16.9×
- 3.8%
- 4.6%
- 0.5%
Profitability
- 85.4%
- 25.8%
- 31.4%
- 38.5%
- 12.6%
- 13.1%
- 14.3%
- 10.8%
- 10.1%
- 42.0%
Growth
- +11.0%
- +6.3%
- +11.3%
- –
- −1.5%
Financial health
- -0.1×
- 0.09
- 6.6%
- 120.4×
- 4.13
- 2.96
- 0.37
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 19%of 952
Top 13%of 884
Top 41%of 601
Top 48%of 886
Top 29%of 987
What analysts expect
- Average price target
- $865.68
- Range
- $700.00 – $1,057.00
- 11 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 29, 2026 | 9.47 | 8.91 | +6.3% |
| Jan 30, 2026 | 11.44 | 10.74 | +6.5% |
| Oct 28, 2025 | 11.83 | 9.65 | +22.6% |
| Aug 1, 2025 | 12.89 | 8.43 | +52.9% |
| Apr 29, 2025 | 8.22 | 8.62 | −4.6% |
| Feb 4, 2025 | 12.07 | 11.21 | +7.7% |
| Oct 31, 2024 | 12.46 | 11.69 | +6.6% |
| Aug 1, 2024 | 11.56 | 10.61 | +9.0% |
0.5%of the share price, paid each year
On $1,000 invested$5a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
8.2% of its profit
Room to growStretchedMore than it earns: 9.8%
News
Strong Dupixent Trajectory Anchors Regeneron Pharmaceuticals’ (REGN) Solid Financial ResultsYahoo Finance · Oct 20, 2026How Much Upside Is Left In Regeneron Stock?Yahoo Finance · Oct 19, 2026Why Regeneron (REGN) Is Up 5.4% After FDA Approves Pasatru For Ultra-Rare FOP TherapyYahoo Finance · Aug 20, 2026Regeneron wins FDA nod for rare bone disorder therapySeeking Alpha · Aug 19, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
5/7Passes 5 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
73Pass
Benjamin Graham
65Pass
Philip Fisher
73Pass
Peter Lynch
37No pass
Joel Greenblatt
35No pass
Charlie Munger
73Pass
Terry Smith
63Pass
Questions about Regeneron Pharmaceuticals
Is Regeneron Pharmaceuticals a good stock to buy?
A strong, very profitable business at a fair price. 5 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Regeneron Pharmaceuticals AI analysis
What does Regeneron Pharmaceuticals do?
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. It is in Biotechnology, based in Tarrytown, NY, United States, with 15,343 employees.
Does Regeneron Pharmaceuticals pay a dividend?
Yes. At today's price the dividend is 0.5% a year, about 8% of its yearly profit. In 2025 it paid out $370 million in dividends.
Is Regeneron Pharmaceuticals stock halal?
Yes. Regeneron Pharmaceuticals passes our halal screen: its business is permitted and its debt is 3% of its market value, under the 30% limit. How we check
How has Regeneron Pharmaceuticals stock done over the past year?
Up 37.5% over the past twelve months, to $955.47. It traded between $600.66 and $973.36, close to its high.
Who are Regeneron Pharmaceuticals's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, CSL and BeOne Medicines. The peers table on this page compares their profit, growth and price with Regeneron Pharmaceuticals's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.